TransMedics Group (NASDAQ:TMDX) PT Lowered to $116.00

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its target price decreased by equities research analysts at JPMorgan Chase & Co. from $173.00 to $116.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 31.07% from the stock's current price.

A number of other research firms have also recently commented on TMDX. Oppenheimer dropped their price target on shares of TransMedics Group from $200.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday. Stephens boosted their target price on TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. Robert W. Baird reduced their price target on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating on the stock in a report on Tuesday. Needham & Company LLC dropped their price objective on TransMedics Group from $208.00 to $109.00 and set a "buy" rating for the company in a report on Tuesday. Finally, Baird R W raised TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $144.80.

TransMedics Group Price Performance

Shares of TransMedics Group stock traded down $37.74 during trading hours on Tuesday, reaching $88.50. The company's stock had a trading volume of 11,660,088 shares, compared to its average volume of 914,126. The firm has a 50 day moving average price of $146.02 and a 200-day moving average price of $140.16. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The stock has a market cap of $2.95 billion, a P/E ratio of 94.15 and a beta of 1.99. TransMedics Group has a one year low of $36.42 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.16). The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company's revenue was up 63.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.12) earnings per share. On average, analysts predict that TransMedics Group will post 1.22 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,180,642.53. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the business's stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company's stock, valued at approximately $3,267,557.11. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,205 shares of company stock valued at $9,981,907. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Amalgamated Bank grew its stake in shares of TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company's stock worth $168,000 after acquiring an additional 70 shares during the last quarter. Pitcairn Co. raised its position in TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company's stock worth $398,000 after buying an additional 78 shares during the last quarter. Harbour Capital Advisors LLC raised its holdings in shares of TransMedics Group by 1.7% during the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company's stock worth $760,000 after purchasing an additional 81 shares during the last quarter. Signaturefd LLC lifted its position in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company's stock valued at $67,000 after purchasing an additional 93 shares during the period. Finally, Arizona State Retirement System grew its position in TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company's stock worth $1,379,000 after purchasing an additional 186 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.